Advertisement
Advertisement
KYMR
Kymera Therapeutics, Inc. Common Stock
120.90
USDSponsored
-1.61
-1.32%
Oct 29, 13:48 UTC -4
Open
Kymera Therapeutics, Inc. Common Stock (KYMR) Earnings
KYMR Earnings Reports
Positive Surprise Ratio
KYMR beat 8 of 25 last estimates.
32%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$3.47M
/-$1.27
Implied change from Q3 26 (Revenue/ EPS)
--
/-3.79%
Implied change from Q4 25 (Revenue/ EPS)
+20.95%
/+30.93%
Kymera Therapeutics, Inc. Common Stock earnings per share and revenue
On Oct 29, 2026, KYMR reported earnings of -1.32 USD per share (EPS) for Q3 26, missing the estimate of -1.29 USD, resulting in a -2.17% surprise. Revenue reached --, compared to an expected 3.11 million, with a -100.00% difference.
Looking ahead to Q4 26, 12 analysts forecast an EPS of -1.27 USD, with revenue projected to reach 3.47 million USD, implying an decrease of -3.79% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
DBV Technologies S.A. - ADR
Report Date
Oct 28, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.70
Surprise
-670.08%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.14
Actual
$0.04
Surprise
+128.27%
Vanda Pharmaceuticals Inc.
Report Date
Oct 28, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.37
Surprise
+46.81%
FAQ
What were Kymera Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Kymera Therapeutics, Inc. Common Stock reported EPS of -$1.32, missing estimates by -2.17%, and revenue of $0.00, -100% below expectations.
How did the market react to Kymera Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Kymera Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Kymera Therapeutics, Inc. Common Stock's next earnings report?
Based on 12
analysts, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$1.27 and revenue of $3.47M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.